2013年10月11日
Localization as an industry and a profession today is a “normal science” — organized around the needs and corporate cultures of mostly Western multinationals, around structures and paradigms built into established computing technologies and around established professional roles and boundaries. This is a world past its definition phase and looking ahead to a future of increasing standardization and commoditization. At the same time, it is a business apparently trapped in a state of permanent fragmentation. Consolidation and scale have proven elusive but the future is not like the past. In the next ten years, two dynamics will play out: technological trends will enable new bases of scale and competitive advantage in managing language; and, an emerging generation of Asia-based (especially China) global companies will have opportunities to leapfrog old approaches. Separately, these megatrends are widely remarked. How they will interact and what these interactions mean for this profession are less considered. This presentation offers and invites speculation on increasingly likely futures.
Click here to read the full article.
About CSOFT Health Sciences
CSOFT Health Sciences, leaders in clinical trial localization, provides AI/ML-enabled medical translation services for all phases of the drug and medical device product lifecycle, from development to post-launch. We also specialize in DCT solutions, linguistic validation, and CTD/eCTD submissions with the FDA, EMA, and NMPA. Our operations are certified in ISO 17100:2015, ISO 9001:2015, and ISO 13485:2016, ensuring our customized solutions meet the rigorous regulatory requirements of MMA, NDA, CTA, and Medical Device Application submissions. www.csoftintl.com